Modulation of HIV reservoirs by host HLA: Bridging the gap between vaccine and cure

Current Opinion in Virology

Volumn 2, Issue 5, 2012, Pages 599-605

  Brumme, Zabrina L ^a,b   Chopera, Denis R ^a,b   Brockman, Mark A ^a,b  

^a SIMON FRASER UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CHETOCIN; CYTOKINE; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 7; PROSTRATIN; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS DNA; VORINOSTAT;

ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE CARRIER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84867399523     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2012.08.003     Document Type: Review

References (92)

1. J.S. Montaner, V.D. Lima, R. Barrios, B. Yip, E. Wood, T. Kerr, K. Shannon, P.R. Harrigan, R.S. Hogg, and P. Daly Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study Lancet 376 2010 532 539
2. Q. Abdool Karim, S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, A.B. Kharsany, S. Sibeko, K.P. Mlisana, and Z. Omar Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 2010 1168 1174
3. R.M. Grant, J.R. Lama, P.L. Anderson, V. McMahan, A.Y. Liu, L. Vargas, P. Goicochea, M. Casapia, J.V. Guanira-Carranza, and M.E. Ramirez-Cardich Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2010 2587 2599
4. K.H. Mayer, and K.K. Venkatesh Antiretroviral therapy as HIV prevention: status and prospects Am J Public Health 100 2010 1867 1876
5. D.M. Margolis Eradication therapies for HIV Infection: time to begin again AIDS Res Hum Retroviruses 27 2011 347 353
6. G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig, K. Allers, T. Schneider, J. Hofmann, C. Kucherer, and O. Blau Long-term control of HIV by CCR5Δ32/Δ32 stem-cell transplantation N Engl J Med 360 2009 692 698
7. K. Allers, G. Hutter, J. Hofmann, C. Loddenkemper, K. Rieger, E. Thiel, and T. Schneider Evidence for the cure of HIV infection by CCR5Δ32/ Δ32 stem cell transplantation Blood 117 2011 2791 2799
8. Two More Nearing AIDS 'Cure' After Bone Marrow Transplants, Doctors Say on World Wide Web URL: http://www.npr.org/blogs/health/2012/07/26/157444649/two- more-nearing-aids-cure-after-bone-marrow-transplants-doctors-say
9. B. Autran, B. Descours, V. Avettand-Fenoel, and C. Rouzioux Elite controllers as a model of functional cure Curr Opin HIV AIDS 6 2011 181 187
10. J. Fellay, K.V. Shianna, D. Ge, S. Colombo, B. Ledergerber, M. Weale, K. Zhang, C. Gumbs, A. Castagna, and A. Cossarizza A whole-genome association study of major determinants for host control of HIV-1 Science 317 2007 944 947
11. J. Fellay, D. Ge, K.V. Shianna, S. Colombo, B. Ledergerber, E.T. Cirulli, T.J. Urban, K. Zhang, C.E. Gumbs, and J.P. Smith Common genetic variation and the control of HIV-1 in humans PLoS Genet 5 2009 e1000791
12. S. Limou, S. Le Clerc, C. Coulonges, W. Carpentier, C. Dina, O. Delaneau, T. Labib, L. Taing, R. Sladek, and C. Deveau Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02) J Infect Dis 199 2009 419 426
13. F. Pereyra, X. Jia, P.J. McLaren, A. Telenti, P.I. de Bakker, B.D. Walker, S. Ripke, C.J. Brumme, S.L. Pulit, and M. Carrington The major genetic determinants of HIV-1 control affect HLA class I peptide presentation Science 330 2010 1551 1557
14. F. Kirchhoff Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses Cell Host Microbe 8 2010 55 67
15. P.J. Goulder, and D.I. Watkins HIV and SIV CTL escape: implications for vaccine design Nat Rev Immunol 4 2004 630 640
16. Q. Sattentau Avoiding the void: cell-to-cell spread of human viruses Nat Rev Microbiol 6 2008 815 826
17. K.P. Burke, and A.L. Cox Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence Immunol Res 47 2010 216 227
18. A. Landi, V. Iannucci, A.V. Nuffel, P. Meuwissen, and B. Verhasselt One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef Curr HIV Res 9 2011 496 504
19. J.M. Carlson, and Z.L. Brumme HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective Microbes Infect 10 2008 455 461
20. P. Ammaranond, D.J. van Bockel, K. Petoumenos, M. McMurchie, R. Finlayson, M.G. Middleton, M.P. Davenport, V. Venturi, K. Suzuki, and L. Gelgor HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcome J Immunol 186 2011 479 488
21. D.Y. Chen, A. Balamurugan, H.L. Ng, W.G. Cumberland, and O.O. Yang Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes Blood 120 2012 100 111
22. E.L. Turnbull, A.R. Lopes, N.A. Jones, D. Cornforth, P. Newton, D. Aldam, P. Pellegrino, J. Turner, I. Williams, and C.M. Wilson HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently J Immunol 176 2006 6130 6146
23. T.M. Allen, X.G. Yu, E.T. Kalife, L.L. Reyor, M. Lichterfeld, M. John, M. Cheng, R.L. Allgaier, S. Mui, and N. Frahm De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection J Virol 79 2005 12952 12960
24. T. Shiina, K. Hosomichi, H. Inoko, and J.K. Kulski The HLA genomic loci map: expression, interaction, diversity and disease J Hum Genet 54 2009 15 39
25. B.S. Taylor, and S.M. Hammer The challenge of HIV-1 subtype diversity N Engl J Med 359 2008 1965 1966
26. Z.L. Brumme, M. John, J.M. Carlson, C.J. Brumme, D. Chan, M.A. Brockman, L.C. Swenson, I. Tao, S. Szeto, and P. Rosato HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins PLoS ONE 4 2009 e6687
27. P. Kiepiela, K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. Moodley, S. Reddy, C. de Pierres, Z. Mncube, and N. Mkhwanazi CD8+ T-cell responses to different HIV proteins have discordant associations with viral load Nat Med 13 2007 46 53
28. R. Zuniga, A. Lucchetti, P. Galvan, S. Sanchez, C. Sanchez, A. Hernandez, H. Sanchez, N. Frahm, C.H. Linde, and H.S. Hewitt Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control J Virol 80 2006 3122 3125
29. J.R. Almeida, D.A. Price, L. Papagno, Z.A. Arkoub, D. Sauce, E. Bornstein, T.E. Asher, A. Samri, A. Schnuriger, and I. Theodorou Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover J Exp Med 204 2007 2473 2485
30. M.C. Iglesias, J.R. Almeida, S. Fastenackels, D.J. van Bockel, M. Hashimoto, V. Venturi, E. Gostick, A. Urrutia, L. Wooldridge, and M. Clement Escape from highly effective public CD8+ T-cell clonotypes by HIV Blood 118 2011 2138 2149
31. H. Chen, Z.M. Nhdlovu, D. Liu, L.C. Porter, J.W. Fang, S. Darko, M.A. Brockman, T. Miura, Z.L. Brumme, and A. Schneidewind TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection Nat Immunol 13 2012 691 700
32. S. Elahi, W.L. Dinges, N. Lejarcegui, K.J. Laing, A.C. Collier, D.M. Koelle, M.J. McElrath, and H. Horton Protective HIV-specific CD8+ T cells evade Treg cell suppression Nat Med 17 2011 989 995
33. S. Elahi, and H. Horton Association of HLA-alleles with the immune regulation of chronic viral infections Int J Biochem Cell Biol 44 2012 1361 1365
34. T. Miura, C.J. Brumme, M.A. Brockman, Z.L. Brumme, F. Pereyra, B.L. Block, A. Trocha, M. John, S. Mallal, and P.R. Harrigan HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers J Virol 83 2009 3407 3412
35. M. Coiras, M.R. Lopez-Huertas, M. Perez-Olmeda, and J. Alcami Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs Nat Rev Microbiol 7 2009 798 812
36. J. Karn The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit Curr Opin HIV AIDS 6 2011 4 11
37. S.K. Choudhary, and D.M. Margolis Curing HIV: Pharmacologic approaches to target HIV-1 latency Annu Rev Pharmacol Toxicol 51 2011 397 418
38. D.D. Richman, D.M. Margolis, M. Delaney, W.C. Greene, D. Hazuda, and R.J. Pomerantz The challenge of finding a cure for HIV infection Science 323 2009 1304 1307
39. S. Palmer, L. Josefsson, and J.M. Coffin HIV reservoirs and the possibility of a cure for HIV infection J Intern Med 270 2011 550 560
40. D. Trono, C. Van Lint, C. Rouzioux, E. Verdin, F. Barre-Sinoussi, T.W. Chun, and N. Chomont HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals Science 329 2010 174 180
41. S.A. Migueles, and M. Connors Small molecules and big killers: the challenge of eliminating the latent HIV reservoir Immunity 36 2012 320 321
42. S.R. Lewin, and C. Rouzioux HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25 2011 885 897
43. T.W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, and T.C. Quinn Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183 188
44. T.W. Chun, D. Engel, M.M. Berrey, T. Shea, L. Corey, and A.S. Fauci Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection Proc Natl Acad Sci U S A 95 1998 8869 8873
45. J.D. Siliciano, J. Kajdas, D. Finzi, T.C. Quinn, K. Chadwick, J.B. Margolick, C. Kovacs, S.J. Gange, and R.F. Siliciano Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells Nat Med 9 2003 727 728
46. N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, F.A. Procopio, B. Yassine-Diab, G. Boucher, M.R. Boulassel, G. Ghattas, and J.M. Brenchley HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation Nat Med 15 2009 893 900
47. S.M. Crowe, and S. Sonza HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication J Leukoc Biol 68 2000 345 350
48. S.M. Crowe Macrophages and residual HIV infection Curr Opin HIV AIDS 1 2006 129 133
49. C.M. Coleman, and L. Wu HIV interactions with monocytes and dendritic cells: viral latency and reservoirs Retrovirology 6 2009 51
50. C.C. Carter, A. Onafuwa-Nuga, L.A. McNamara, J.T. Riddell, D. Bixby, M.R. Savona, and K.L. Collins HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs Nat Med 16 2010 446 451
51. J.K. Wong, C.C. Ignacio, F. Torriani, D. Havlir, N.J. Fitch, and D.D. Richman In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues J Virol 71 1997 2059 2071
52. P. Lerner, M. Guadalupe, R. Donovan, J. Hung, J. Flamm, T. Prindiville, S. Sankaran-Walters, M. Syvanen, J.K. Wong, and M.D. George The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy J Virol 85 2011 4772 4782
53. K.G. Lassen, A.M. Hebbeler, D. Bhattacharyya, M.A. Lobritz, and W.C. Greene A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs PLoS ONE 7 2012 e30176
54. A. Jordan, P. Defechereux, and E. Verdin The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation EMBO J 20 2001 1726 1738
55. S. Yukl, S. Pillai, P. Li, K. Chang, W. Pasutti, C. Ahlgren, D. Havlir, M. Strain, H. Gunthard, and D. Richman Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity Virology 387 2009 98 108
56. R.M. van der Sluis, G. Pollakis, M.L. van Gerven, B. Berkhout, and R.E. Jeeninga Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter Retrovirology 8 2011 73
57. A. Narayanan, K. Kehn-Hall, C. Bailey, and F. Kashanchi Analysis of the roles of HIV-derived microRNAs Expert Opin Biol Ther 11 2011 17 29
58. R. Triboulet, B. Mari, Y.L. Lin, C. Chable-Bessia, Y. Bennasser, K. Lebrigand, B. Cardinaud, T. Maurin, P. Barbry, and V. Baillat Suppression of microRNA-silencing pathway by HIV-1 during virus replication Science 315 2007 1579 1582
59. F. Wightman, P. Ellenberg, M. Churchill, and S.R. Lewin HDAC inhibitors in HIV Immunol Cell Biol 90 2012 47 54
60. D.M. Margolis Histone deacetylase inhibitors and HIV latency Curr Opin HIV AIDS 6 2011 25 29
61. U. Mbonye, and J. Karn Control of HIV latency by epigenetic and non-epigenetic mechanisms Curr HIV Res 9 2011 554 567
62. K.G. Lassen, K.X. Ramyar, J.R. Bailey, Y. Zhou, and R.F. Siliciano Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells PLoS Pathog 2 2006 e68
63. F. Wolschendorf, A. Bosque, T. Shishido, A. Duverger, J. Jones, V. Planelles, and O. Kutsch Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-kappaB activity J Virol 86 2012 4548 4558
64. G. Lehrman, I.B. Hogue, S. Palmer, C. Jennings, C.A. Spina, A. Wiegand, A.L. Landay, R.W. Coombs, D.D. Richman, and J.W. Mellors Depletion of latent HIV-1 infection in vivo: a proof-of-concept study Lancet 366 2005 549 555
65. X. Contreras, M. Schweneker, C.S. Chen, J.M. McCune, S.G. Deeks, J. Martin, and B.M. Peterlin Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells J Biol Chem 284 2009 6782 6789
66. N.M. Archin, A. Espeseth, D. Parker, M. Cheema, D. Hazuda, and D.M. Margolis Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid AIDS Res Hum Retroviruses 25 2009 207 212
67. J. Blazkova, K. Trejbalova, F. Gondois-Rey, P. Halfon, P. Philibert, A. Guiguen, E. Verdin, D. Olive, C. Van Lint, and J. Hejnar CpG methylation controls reactivation of HIV from latency PLoS Pathog 5 2009 e1000554
68. S. Bouchat, J.S. Gatot, K. Kabeya, C. Cardona, L. Colin, G. Herbein, S. de Wit, N. Clumeck, O. Lambotte, and C. Rouzioux Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1+ HAART-treated patients AIDS 26 2012 1473 1482
69. F.X. Wang, Y. Xu, J. Sullivan, E. Souder, E.G. Argyris, E.A. Acheampong, J. Fisher, M. Sierra, M.M. Thomson, and R. Najera IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART J Clin Invest 115 2005 128 137
70. D.D. Scripture-Adams, D.G. Brooks, Y.D. Korin, and J.A. Zack Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype J Virol 76 2002 13077 13082
71. S. Reuse, M. Calao, K. Kabeya, A. Guiguen, J.S. Gatot, V. Quivy, C. Vanhulle, A. Lamine, D. Vaira, and D. Demonte Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection PLoS ONE 4 2009 e6093
72. A.L. Remoli, G. Marsili, A. Battistini, and M. Sgarbanti The development of immune-modulating compounds to disrupt HIV latency Cytokine Growth Factor Rev 23 2012 159 172
73. J.D. Siliciano, J. Lai, M. Callender, E. Pitt, H. Zhang, J.B. Margolick, J.E. Gallant, J. Cofrancesco Jr., R.D. Moore, and S.J. Gange Stability of the latent reservoir for HIV-1 in patients receiving valproic acid J Infect Dis 195 2007 833 836
74. N. Sagot-Lerolle, A. Lamine, M.L. Chaix, F. Boufassa, J.P. Aboulker, D. Costagliola, C. Goujard, C. Pallier, J.F. Delfraissy, and O. Lambotte Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir AIDS 22 2008 1125 1129
75. N.M. Archin, J.J. Eron, S. Palmer, A. Hartmann-Duff, J.A. Martinson, A. Wiegand, N. Bandarenko, J.L. Schmitz, R.J. Bosch, and A.L. Landay Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells AIDS 22 2008 1131 1135
76. J.P. Routy, C.L. Tremblay, J.B. Angel, B. Trottier, D. Rouleau, J.G. Baril, M. Harris, S. Trottier, J. Singer, and N. Chomont Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study HIV Med 13 2012 291 296
77. R.L. Murphy, B. Autran, C. Katlama, G. Brucker, P. Debre, V. Calvez, B. Clotet, N. Clumeck, D. Costagliola, and S.G. Deeks A step ahead on the HIV collaboratory Science 324 2009 1264 1265
78. N.M. Archin, A.L. Liberty, A.D. Kashuba, S.K. Choudhary, J.D. Kuruc, A.M. Crooks, D.C. Parker, E.M. Anderson, M.F. Kearney, and M.C. Strain Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 487 2012 482 485
79. N.M. Archin, M. Cheema, D. Parker, A. Wiegand, R.J. Bosch, J.M. Coffin, J. Eron, M. Cohen, and D.M. Margolis Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection PLoS ONE 5 2010 e9390
80. L. Shan, K. Deng, N.S. Shroff, C.M. Durand, S.A. Rabi, H.C. Yang, H. Zhang, J.B. Margolick, J.N. Blankson, and R.F. Siliciano Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation Immunity 36 2012 491 501
81. F. Garcia 'Functional cure' of HIV infection: the role of immunotherapy Immunotherapy 4 2012 245 248
82. S.G. Kitchen, B.R. Levin, G. Bristol, V. Rezek, S. Kim, C. Aguilera-Sandoval, A. Balamurugan, O.O. Yang, and J.A. Zack In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells PLoS Pathog 8 2012 e1002649
83. U.V. Comandini, A. Sonnerborg, A. Vahlne, and Z. Yun Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR J Virol Methods 69 1997 171 180
84. E.H. Graf, A.M. Mexas, J.J. Yu, F. Shaheen, M.K. Liszewski, M. Di Mascio, S.A. Migueles, M. Connors, and U. O'Doherty Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART PLoS Pathog 7 2011 e1001300
85. B. Descours, V. Avettand-Fenoel, C. Blanc, A. Samri, A. Melard, V. Supervie, I. Theodorou, G. Carcelain, C. Rouzioux, and B. Autran Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells Clin Infect Dis 54 2012 1495 1503
86. C. Dalmasso, W. Carpentier, L. Meyer, C. Rouzioux, C. Goujard, M.L. Chaix, O. Lambotte, V. Avettand-Fenoel, S. Le Clerc, and L.D. de Senneville Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study PLoS ONE 3 2008 e3907
87. D. Mendoza, S.A. Johnson, B.A. Peterson, V. Natarajan, M. Salgado, R.L. Dewar, P.D. Burbelo, N.A. Doria-Rose, E.H. Graf, and J.H. Greenwald Comprehensive analysis of unique cases with extraordinary control over HIV replication Blood 119 2012 4645 4655
88. A. Saez-Cirion, C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia, F. Boufassa, F. Barre-Sinoussi, J.F. Delfraissy, M. Sinet, and G. Pancino HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype Proc Natl Acad Sci U S A 104 2007 6776 6781
89. T. Whittall, B. Peters, D. Rahman, C.I. Kingsley, R. Vaughan, and T. Lehner Immunogenic and tolerogenic signatures in human immunodeficiency virus (HIV)-infected controllers compared with progressors and a conversion strategy of virus control Clin Exp Immunol 166 2011 208 217
90. M. Lichterfeld, D. Mou, T.D. Cung, K.L. Williams, M.T. Waring, J. Huang, F. Pereyra, A. Trocha, G.J. Freeman, and E.S. Rosenberg Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors Blood 112 2008 3679 3687
91. D.E. Kaufmann, D.G. Kavanagh, F. Pereyra, J.J. Zaunders, E.W. Mackey, T. Miura, S. Palmer, M. Brockman, A. Rathod, and A. Piechocka-Trocha Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction Nat Immunol 8 2007 1246 1254
92. D.E. Kaufmann, and B.D. Walker PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention J Immunol 182 2009 5891 5897